TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the ...

Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing ...

Three abstracts were presented from Photocure's U.S. Blue Light Cystoscopy with Cysview Registry, a large multicenter bladder cancer patient registry of real-world data, established by Photocure in ...

The RTF letter was unexpected, especially considering the positive feedback and unanimous encouragement ImmunityBio received ...

NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions.

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

Lightweight, high-precision AI model effectively overcomes two major barriers to AI deployment in bladder cancer care: Low detection rates for difficult-to-identify lesions. Prohibitive computational ...

These lesions (335 in total) included carcinoma in-situ (CIS) (145; 43%), low-grade Ta (53 ... with NMIBC Undergoing Blue Light Cystoscopy-Aided Transurethral Resection of Bladder Tumor" by Boris ...

Papillary disease is estimated to be approximately 6-10 times more common than bladder cancer CIS, representing a large patient population that may benefit from ANKTIVA plus BCG. 1 About the QUILT ...

The ongoing phase 2b SunRISe-1 study is assessing TAR-200 intravesical gemcitabine delivery in patients with BCG-unresponsive high-risk NMIBC.